BioSpace News Archive

Bio NC

Aerie Pharmaceuticals to Present at the NASDAQ 38th Investor Conference

Mr. Rubino will provide an Aerie overview and business update.

June 6, 2018
·
2 min read
FDA

Partner Therapeutics (PTx) Announces US FDA Approval of Leukine® (sargramostim) for the Treatment of Acute Radiation Syndrome

Improves survival when initiated 48 hours after radiation exposure

June 6, 2018
·
8 min read
Business

ReShape Lifesciences Assembles World Class Scientific Advisory Board

ReShape Lifesciences Inc. announced the formation of the Company’s Scientific Advisory Board (SAB)

June 6, 2018
·
5 min read
Policy

AMRI Secures Seven-year NIH Contract from the National Institute of Allergy and Infectious Diseases

AMRI has secured a seven-year contract from the National Institute of Allergy and Infectious Disease (NIAID), part of the National Institutes of Health (NIH).

June 6, 2018
·
1 min read
Drug Development

Daiichi Sankyo to Present Late-Breaking Phase 3 Data for Single Agent Quizartinib in Patients with Relapsed/Refractory AML with FLT3-ITD Mutations at Plenary Session at EHA 2018

Data from QuANTUM-R study demonstrating single agent quizartinib significantly prolongs overall survival compared to salvage chemotherapy in patients with relapsed/refractory acute myeloid leukemia (AML) with FLT3-ITD mutations to be unveiled

June 6, 2018
·
7 min read
Business

Gallagher Student Health partners with SilverCloud Health to bring behavioral health services to college campuses

Clinically-validated online platform helps students get faster, more focused care from their dorms as cases of depression, anxiety and stress reach epidemic levels

June 6, 2018
·
3 min read
Drug Development

Spyryx SPX-101 Phase 2 HOPE-1 Trial Shows Improvement in Lung Function in Patients with Cystic Fibrosis via Novel Modulation of ENaC

Inhaled drug can be used regardless of a patient’s particular CF mutation

June 6, 2018
·
4 min read
Policy

Takeda and TiGenix Announce Results of First Acceptance Period for the Voluntary and Conditional Public Takeover Bid of TiGenix and Commencement of Second Acceptance Period

Takeda Pharmaceutical Company Limited and TiGenix NV today announced the results of the first acceptance period of Takeda’s previously announced tender offer in cash for all outstanding ordinary shares, warrants and American Depositary Shares of TiGenix that are not yet owned by Takeda and its affiliates.

June 6, 2018
·
12 min read
Pharm Country

SS&C to Speak at June 2018 Investor Conferences

SS&C Technologies announced that the following executives will host 1-on-1 meetings and present at June investor conferences

June 6, 2018
·
1 min read
Business

Sonion and Valencell Partner to Make Biometrics Universal in Hearables and Hearing Health Markets

Market leaders joining forces to accelerate innovation in the rapidly expanding market for health, medical and consumer devices

June 6, 2018
·
4 min read